Regulatory authorities, including the US Food and Drug Administration (FDA), 
have accelerated diagnostic and therapeutic approvals during the coronavirus 
disease 2019 (COVID-19) pandemic. Accelerated clinical development and approvals 
have resulted in vaccine programs for severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). However, some individuals remain at high risk for 
the progression of COVID-19. In the US, the FDA has given Emergency Use 
Authorization (EUA) for two neutralizing therapeutic monoclonal antibody 
'cocktails,' casirivimab and imdevimab (REGEN-COV), bamlanivimab and etesevimab, 
and one monotherapy, bamlanivimab, for prophylactic post-exposure therapy in 
individuals at high risk of progressing to severe COVID-19. Preclinical and 
clinical studies showed consistent effectiveness of REGEN-COV against current 
variants of SARS-CoV-2. On 21st November 2020, the FDA approved an initial EUA 
for REGEN-COV to treat mild to moderate COVID-19 in adults and in children 12 
years or older with exposure to SARS-CoV-2 at high risk for progression to 
severe COVID-19. On 30th July 2021, the FDA updated its EUA for REGEN-COV for 
emergency use as post-exposure prophylactic to prevent COVID-19 progression in 
adults and children aged 12 years or older. This Editorial aims to provide an 
update on accelerated regulatory authorization for post-exposure prophylactic 
neutralizing monoclonal antibodies to SARS-CoV-2 for individuals at high risk 
for COVID-19.